BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15289353)

  • 21. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
    Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
    Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Construction and characterization of osteosarcoma 9901 cell cDNA library].
    Liao B; Ma BA; Zhang HZ; Long H; Fan DG; Fan QY
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Nov; 19(6):598-600. PubMed ID: 15182661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes.
    Suemori K; Fujiwara H; Ochi T; Azuma T; Yamanouchi J; Narumi H; Yakushijin Y; Hato T; Hasegawa H; Yasukawa M
    Cancer Sci; 2008 Jul; 99(7):1414-9. PubMed ID: 18422754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients.
    Jin M; Komohara Y; Shichijo S; Harada M; Yamanaka R; Miyamoto S; Nikawa J; Itoh K; Yamada A
    Oncol Rep; 2008 May; 19(5):1277-83. PubMed ID: 18425388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.
    Maia S; Haining WN; Ansén S; Xia Z; Armstrong SA; Seth NP; Ghia P; den Boer ML; Pieters R; Sallan SE; Nadler LM; Cardoso AA
    Cancer Res; 2005 Nov; 65(21):10050-8. PubMed ID: 16267031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity.
    Jin S; Wang Y; Zhang Y; Zhang HZ; Wang SJ; Tang JQ; Chen HJ; Ge HL
    Cancer Sci; 2008 Aug; 99(8):1670-8. PubMed ID: 18754882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
    Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
    Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
    Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
    Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a novel prostate cancer-associated tumor antigen.
    Miles AK; Rogers A; Li G; Seth R; Powe D; McArdle SE; McCulloch TA; Bishop MC; Rees RC
    Prostate; 2007 Feb; 67(3):274-87. PubMed ID: 17192878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of T cell receptor-engineered T cells targeting the sarcoma-associated antigen papillomavirus binding factor.
    Hamada S; Tsukahara T; Watanabe Y; Murata K; Mizue Y; Kubo T; Kanaseki T; Hirohashi Y; Emori M; Nakatsugawa M; Teramoto A; Yamashita T; Torigoe T
    Cancer Sci; 2024 Jan; 115(1):24-35. PubMed ID: 37879364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
    Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
    Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
    Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
    Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parathyroid hormone-related protein as a common target molecule in specific immunotherapy for a wide variety of tumor types.
    Arima Y; Matsueda S; Yano H; Harada M; Itoh K
    Int J Oncol; 2005 Oct; 27(4):981-8. PubMed ID: 16142314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of an HLA-A*0201 restricted Bcl2-derived epitope expressed on tumors.
    Wang M; Johansen B; Nissen MH; Thorn M; Kløverpris H; Fomsgaard A; Buus S; Claësson MH
    Cancer Lett; 2007 Jun; 251(1):86-95. PubMed ID: 17182178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587.
    Xing Q; Pang XW; Peng JR; Yin YH; Li Y; Yu X; Zhou SP; Zhang Y; Chen WF
    Biochem Biophys Res Commun; 2008 Jul; 372(2):331-5. PubMed ID: 18498761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.